ArticleFrontiers in immunology2026
Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There has been an annual rise in the incidence of primary membranous nephropathy (PMN), a common pathological type of nephrotic syndrome (NS). Obinutuzumab is a humanised, glycosylated, type II anti-CD20 monoclonal antibody. Characterised by its enhanced B-cell depletion capability compared with rituximab (RTX), obinutuzumab has demonstrated promising efficacy in the treatment of membranous nephropathy. Objective: This study aimed to investigate the efficacy and safety of obinutuzumab in treating various subtypes of PMN. Methods: A total of 94 PMN patients with NS were enrolled in this study. Based on their treatment history before receiving obinutuzumab, the patients were categorised into the Initial therapy group (group A, n=32), the Refractory group (group B, n=32), and the Remedial therapy group (group C, n=30). The efficacy and safety of obinutuzumab treatment after a 24-month follow-up period were observed and analysed in each group. The primary endpoint was the clinical remission rate (complete remission + partial remission) at 24 months, and the secondary endpoints were treatment safety and the incidence of treatment-emergent adverse events. Results: Following 24 months of obinutuzumab therapy, 95.74% (90/94) of the PMN patients achieved clinical remission, with 28.72% (27/94) reaching complete remission (CR) and 67.02% (63/94) achieving partial remission (PR). The Initial therapy group (group A) achieved a 100% (32/32) clinical remission rate: 37.5% (12/32) attained CR, and 62.5% (20/32) attained PR. The Refractory group (group B) achieved a 96.88% (31/32) clinical remission rate: 25% (8/32) attained CR, and 71.88% (23/32) attained PR. The Remedial therapy group (group C) achieved a 90% (27/30) clinical remission rate: 23.33% (7/30) attained CR, and 66.67% (20/30) attained PR. All 63 anti-PLA2R antibody-positive (>20 U/mL) patients and 16 anti-PLA2R antibody negativity but no immunological remission (2-20 U/mL) patients demonstrated declining antibody levels following obinutuzumab therapy, and 68.4% (54/79) attained complete immunological remission (<2 U/mL). Conclusion: Obinutuzumab demonstrates high clinical remission rates and acceptable safety in PMN patients, with good efficacy even in refractory and RTX-resistant patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.